

References

I-25

1. Koo TY, Yang J. Current progress in ABO-incompatible kidney transplantation. *Kidney Res Clin Pract.* 2015;34:170-179.
2. Klein C, Brennan DC. HLA and ABO sensitization and desensitization in renal transplantation. UpToDate. Last updated January 8, 2021.
3. Krishnan NS, Zehnder D, Briggs D, Higgins R. Human leukocyte antigen antibody incompatible renal transplantation. *IJN.* 2014:409-414.
4. Zachary AA, Leffell MS. Desensitization for solid organ and hematopoietic stem cell transplantation. *Immunol Rev.* 2014;258: 183–207.
5. Sethi S, Choi J, Toyoda M, Vo A, Peng A, Jordan SC. Desensitization: overcoming the immunologic barriers to transplantation. *Immunol Res.* 2017; 2017:1-11.
6. Jordan SC, Lorant T, Choi J, Kjellman C. IgG endopeptidase in highly sensitized patients undergoing transplantation. *NEJM.* 2017;377:442-453.
7. Green H, Neshet E, Aizner S, et al. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients. *Clin Transplant.* 2019;33(6):1-13.
8. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Rituximab. 2020.
9. Micromedex DrugDex Compendium®. -2024. Rituximab.
10. Sasaki H, Hotta K, Mitsuke A, et al. Long-Term outcome of ABO-incompatible kidney transplantation in patients treated with low-dose rituximab regimen. *Transplant Proc.* 2021;53(3):989-994.